Holen Sie sich die Stockscreener-App
2.92
2.99%
-0.09
Vorhandelsmarkt:
2.86
-0.06
-2.05%
Schlusskurs vom Vortag:
$3.01
Offen:
$2.9
24-Stunden-Volumen:
7.13M
Relative Volume:
2.01
Marktkapitalisierung:
$439.08M
Einnahmen:
$2.82M
Nettoeinkommen (Verlust:
$-114.60M
KGV:
-3.2294
EPS:
-0.9042
Netto-Cashflow:
$-81.94M
1W Leistung:
+2.10%
1M Leistung:
+6.57%
6M Leistung:
+10.19%
1J Leistung:
-4.89%
1-Tages-Spanne:
$2.80
$3.11
1-Wochen-Bereich:
$2.79
$3.20
52-Wochen-Spanne:
$2.01
$5.228
Absci Corp Stock (ABSI) Company Profile
Firmenname
Absci Corp
Sektor
Branche
Telefon
(360) 949-1041
Adresse
18105 SE MILL PLAIN BLVD, VANCOUVER
Compare ABSI vs VRTX, REGN, ALNY, ARGX, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ABSI
Absci Corp
|
2.92 | 439.08M | 2.82M | -114.60M | -81.94M | -0.9042 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Absci Corp Stock (ABSI) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-08 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-10-02 | Eingeleitet | JP Morgan | Overweight |
| 2025-07-03 | Fortgesetzt | Morgan Stanley | Overweight |
| 2025-01-22 | Eingeleitet | Needham | Buy |
| 2024-10-02 | Eingeleitet | Guggenheim | Buy |
| 2024-07-03 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-03-14 | Eingeleitet | Scotiabank | Sector Outperform |
| 2023-12-05 | Eingeleitet | KeyBanc Capital Markets | Overweight |
| 2023-05-04 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-08-12 | Herabstufung | JP Morgan | Overweight → Underweight |
| 2022-07-18 | Eingeleitet | Truist | Buy |
| 2022-03-02 | Fortgesetzt | Cowen | Market Perform |
| 2022-02-01 | Eingeleitet | Berenberg | Buy |
| 2021-11-10 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2021-10-15 | Fortgesetzt | Cowen | Market Perform |
| 2021-08-16 | Eingeleitet | BofA Securities | Neutral |
| 2021-08-16 | Eingeleitet | Cowen | Market Perform |
| 2021-08-16 | Eingeleitet | Credit Suisse | Outperform |
| 2021-08-16 | Eingeleitet | Stifel | Hold |
Alle ansehen
Absci Corp Aktie (ABSI) Neueste Nachrichten
Absci, DigitalOcean and other big stocks moving lower in Wednesday's pre-market session - MSN
Absci price target lowered to $4.20 from $4.32 at Morgan Stanley - TipRanks
A Quick Look at Today's Ratings for Absci Corp(ABSI.US), With a Forecast Between $4.2 to $8 - 富途牛牛
Absci (NASDAQ:ABSI) Given "Buy" Rating at Needham & Company LLC - MarketBeat
Absci, DigitalOcean And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Benzinga
Why Blaize Holdings Shares Are Trading Higher By Around 41%; Here Are 20 Stocks Moving Premarket - Benzinga
Absci Reports Positive ABS-201 Clinical Progress, Strong Financials, and Advances AI-Designed Therapeutics Pipeline in 2025 Results - Minichart
Absci Corp (ABSI) Q4 2025 Earnings Call Highlights: Strategic Advances and Financial Resilience By GuruFocus - Investing.com Canada
TD Cowen Maintains Absci Corp(ABSI.US) With Buy Rating - Moomoo
Absci reports Q4 EPS (20c), consensus (17c) - TipRanks
Absci’s AI-Native Integrated Drug Creation Platform: Advancing Antibody Therapeutics and Biopharma Innovation - Minichart
Absci Corporation (ABSI) reports Q4 loss, misses revenue estimates - MSN
Absci Corp’s 2025 Q4 Call: FDA Delays, Oncology Partnership Shifts, and ABS-201 Timeline Contradictions - Bitget
Absci Q4 Earnings Call Highlights - Yahoo Finance
Earnings call transcript: Absci’s Q4 2025 earnings miss forecasts, stock dips - Investing.com
Absci Corp reports results for the quarter ended December 31Earnings Summary - TradingView
Absci Corporation (ABSI) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance
Absci Corp. (NASDAQ:ABSI) Reports Mixed Q4 Results Amid Clinical Progress - ChartMill
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
Absci (NASDAQ: ABSI) deepens 2025 loss while pushing ABS-201 toward key data - Stock Titan
Absci earnings missed by $0.02, revenue fell short of estimates - Investing.com
Absci (NASDAQ:ABSI) Issues Quarterly Earnings Results, Misses Estimates By $0.04 EPS - MarketBeat
Absci shares slip nearly 4% on Q4 revenue miss, wider loss than expected - Investing.com
Absci 10-K: Partner revenue $2.8M, Net loss $115.2M, EPS $(0.84) - TradingView
ABSCI ($ABSI) Releases Q4 2025 Earnings - Quiver Quantitative
Absci (NASDAQ: ABSI) highlights ABS-201 trial progress and AI drug platform - Stock Titan
Absci's hair-loss drug is well tolerated in first 3 cohorts - Stock Titan
AbSci Corp options imply 13.4% move in share price post-earnings - TipRanks
Absci forms advisory board for endometriosis drug program - Investing.com
Absci taps Yale, Mayo experts for non-hormonal endometriosis drug - Stock Titan
Earnings Scheduled For March 24, 2026 - Benzinga
Absci Q4 2025 Earnings Call Transcript - MarketBeat
Earnings To Watch: Absci Corp (ABSI) Reports Q4 2025 Result - GuruFocus
ABSI Technical Analysis | Trend, Signals & Chart Patterns | ABSCI CORP (NASDAQ:ABSI) - ChartMill
Form 8K Absci Corp For: 14 January - Investing.com
Absci Corp expected to post a loss of 19 cents a shareEarnings Preview - TradingView
ABSI PE Ratio & Valuation, Is ABSI Overvalued - Intellectia AI
ABSI Forecast, Price Target & Analyst Ratings | ABSCI CORP (NASDAQ:ABSI) - ChartMill
Earnings Preview: Absci Corp to Report Financial Results Post-market on March 24 - 富途牛牛
Needham Maintains Absci Corp(ABSI.US) With Buy Rating, Maintains Target Price $7 - 富途牛牛
Needham Reiterates Buy Rating for Absci (ABSI) with Unchanged Pr - GuruFocus
Absci (NASDAQ:ABSI) Given Buy Rating at Needham & Company LLC - MarketBeat
Heights Capital Management Inc. Makes New Investment in Absci Corporation $ABSI - MarketBeat
Absci Corporation (NASDAQ:ABSI) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Absci (ABSI) CLO receives major RSU and stock option grants - Stock Titan
Absci (NASDAQ: ABSI) CFO receives new RSU and stock option awards - Stock Titan
Absci (NASDAQ: ABSI) SVP Bedrick gets RSUs, options and tax withholding - Stock Titan
Absci (NASDAQ: ABSI) CEO granted 2M+ equity units and has shares withheld for taxes - Stock Titan
Absci Corp chief innovation officer Busch buys $229,000 in stock By Investing.com - Investing.com Australia
Absci (NASDAQ:ABSI) Insider Acquires $229,000.00 in Stock - MarketBeat
Absci Corp chief innovation officer Busch buys $229,000 in stock - Investing.com India
Finanzdaten der Absci Corp-Aktie (ABSI)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):